Targeting cancer cell metabolism in pancreatic adenocarcinoma
Metrics: PDF 4499 views | HTML 4567 views | ?
Romain Cohen1, Cindy Neuzillet1,2, Annemilaï Tijeras-Raballand3, Sandrine Faivre4, Armand de Gramont5, Eric Raymond4
1INSERM U728, Beaujon University Hospital (AP-HP – PRES Paris 7 Diderot), Clichy La Garenne, France
2Department of Medical Oncology, Henri Mondor University Hospital, Créteil, France
3AAREC Filia Research, Translational Department, Boulogne-Billancourt, France
4Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
5New Drug Evaluation Laboratory, Centre of Experimental Therapeutics and Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Eric Raymond, e-mail: [email protected]
Keywords: glycolysis, warburg effect, metformin, glutamine, hypoxia
Received: March 08, 2015 Accepted: May 29, 2015 Published: June 10, 2015
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent need to explore innovative treatment strategies. Due to specific microenvironment constraints including an extensive desmoplastic stroma reaction, PDAC faces major metabolic challenges, principally hypoxia and nutrient deprivation. Their connection with oncogenic alterations such as KRAS mutations has brought metabolic reprogramming to the forefront of PDAC therapeutic research. The Warburg effect, glutamine addiction, and autophagy stand as the most important adaptive metabolic mechanisms of cancer cells themselves, however metabolic reprogramming is also an important feature of the tumor microenvironment, having a major impact on epigenetic reprogramming and tumor cell interactions with its complex stroma. We present a comprehensive overview of the main metabolic adaptations contributing to PDAC development and progression. A review of current and future therapies targeting this range of metabolic pathways is provided.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.